 interferon alfa doxorubicin treatment advanced cervical cancer Interferon alfa doxorubicin synergistic effects vitro cells cervical cancers clinical trial interferon alfa doxorubicin patients advanced recurrent cervical cancers patients interferon alfa units square meter units square meter infusion period hour doxorubicin period Treatments weekly weeks Initial response evaluation week treatment every-other-week schedule patients favorable responses stable disease Bone marrow hepatic renal toxicities minimal Fever malaise major sources toxicity evaluable patients clinical partial responses responders years survival regimen patients advanced cervical cancers